PRM157 - THE IMPACT OF LANDMARK RESPONSE ON OVERALL SURVIVAL: IMPLICATIONS FOR THE ECONOMIC EVALUATION OF IMMUNE-THERAPY (I-O) TREATMENT IN SMALL CELL LUNG CANCER (SCLC)